PhaseRx, Inc.

Equities

PZRXQ

US71723F1030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:42:58 2023-09-21 am EDT			5-day change	1st Jan Change
0.0002 ^USD	-.--%		-.--%	-.--%

2019	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
2018	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

PhaseRx Considers Multiple Alternatives

December 14, 2017 at 12:00 am EST

PhaseRx, Inc. (NasdaqCM:PZRX) is exploring multiple strategic alternatives. "The protection afforded under a Chapter 11 filing enables us to continue to explore strategic alternatives, including a potential merger transaction," President and Chief Executive Officer Robert Overell said in a news release. PhaseRx has hired Cowen and Company, LLC to find a buyer.

Latest news about PhaseRx, Inc.

Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	19-01-30	CI
PhaseRx, Inc. Bankruptcy Case Dismissed	18-03-23	CI
Motion for Case Dismissal Filed for PhaseRx, Inc.	18-03-06	CI
Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	18-02-20	CI
PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	18-02-02	CI
Motion for Asset Sale Approved for PhaseRx, Inc.	18-02-01	CI
Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	18-01-31	CI
Bidding Procedure Approved for PhaseRx, Inc.	17-12-27	CI
PhaseRx Considers Multiple Alternatives	17-12-14	CI
PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	17-12-13	CI
PhaseRx, Inc. Filed for Bankruptcy	17-12-11	CI
Motion for Asset Sale Filed by PhaseRx, Inc.	17-12-11	CI
PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-09	CI
Phaserx, Inc. Announces Termination of Michael Houston as Chief Scientific Officer	17-10-13	CI
PhaseRx, Inc. Announces Reduction of Workforce by 10 Employees	17-10-13	CI
PhaseRx Seeks Corporate Restructuring And Alternatives	17-10-13	CI
Phaserx To Cut Half Its Workforce, Looks Into Potential Merger	17-10-13	CI
PhaseRx, Inc. Appoints Robert W. Overell as Principal Accounting Officer	17-09-26	CI
PhaseRx, Inc. Announces Resignation of Shing-Yin Tsui as Senior Vice President, Finance, Secretary and Principal Accounting Officer, Effective as of September 15, 2017	17-09-08	CI
Phaserx Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-10	CI
PhaseRx, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-11	CI
PhaseRx, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-03-27	CI
Certain Preferred Stock of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	16-11-13	CI
Certain Warrants of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	16-11-13	CI
Certain Stock Options of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	16-11-13	CI

Chart PhaseRx, Inc.

Duration

Period

More charts

Company Profile

Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHASERX, INC.	-.--%	2.34K
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs